ANAB Hisse Senedi Fiyat Grafiği
ANAB Kazanmak
AnaptysBio Inc
$66.11
-0.72%
$-0.48
Kapanışta: Apr 28, 16:00:00 GMT-4
$66.4
0.43%
$0.29
Ön Piyasa: Apr 29, 06:31:06 GMT-4
Geri
AnaptysBio Inc (ANAB) Kazanmak
Önemli İstatistikler
Önceki Kapanış
$66.59
Açılış fiyatı
$67.16
Günün Aralığı
$65.06 - $71.67
52 haftalık aralık
$15.4 - $69.1
İşlem hacmi
740.5K
Ort.Hacim
556.7K
Dividend yield
--
EPS (TTM)
-0.32
Piyasa Değeri
$1.9B
ANAB nedir?
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. The company has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
